2026 Oncology Coding Guide for Physician Groups

Your Q1 2026 commercial remits came in lower than Q1 2025 for the same case mix. You ran the same regimens in the same chairs, your coders submitted the same CPTs, and the deposits are 10 to 40 percent lighter. The reason is sitting in the 2026 CPT bundling rollout that most commercial payers have not repriced their fee schedules to match.

According to AJMC, an ASTRO survey in early 2026 found that more than two-thirds of physicians reported 10 percent or higher cuts to commercial reimbursement after the 2026 CPT changes, with some clinics reporting Q1 revenue down 30 to 40 percent. Todd Doyle, MD, President of New York Oncology Hematology and Chief of Radiation Oncology at OneOncology, told AJMC his network warned every major commercial payer in November and December and still saw retroactive denials in February.

"Some said yes, some said no, and even the ones when they said no, then went back and denied those claims afterwards. So, it was a huge dropping of the ball that the payers didn't revalue their codes."

• Todd Doyle, MD, President, New York Oncology Hematology, AJMC

This oncology coding guide gives you the code-set fundamentals, the 2026 changes that are actively breaking remits, and the revenue leaks every community practice tracks this quarter. Section 1 covers what changed in 2026. Sections 2 through 5 cover ICD-10 sequencing, the chemo administration CPT hierarchy, radiation oncology coding, and drug billing in its ASP+6% context. Section 6 closes with the three revenue leaks coding drives and the KPIs to monitor each one.

What changed in oncology coding for 2026

The biggest 2026 oncology coding change is the bundling of several radiation oncology CPT codes that commercial payers have not yet matched on their fee schedules, which is producing retroactive denials and silent underpayment in Q1 remits. The Doyle interview describes the pattern: warning, partial cooperation, then denial.

A working list of the 2026 changes a practice owner audits this month:

1. Radiation oncology CPT bundling. Treatment delivery codes including 77402, 77407, and 77412 were repriced for 2026. Confirm your commercial payer fee schedules reflect the Medicare repricing. Where they do not, every claim filed since January 1 is a candidate for an underpayment recovery letter.
2. Mechanical scalp cooling CPT codes 97007, 97008, and 97009. New Category I CPT codes effective 2026 replace the 2021 Category III codes. Confirm your scalp cooling vendor's documentation captures setup, pre-cooling, and post-cooling time separately.
3. CAR-T cell therapy administration CPT codes 38225 through 38228. Effective 2025, these four Category I codes give practices granular reporting for collection, receipt, preparation, and administration of CAR-T cell products. Per-dose drug cost frequently exceeds $400,000, so denial recovery on a single CAR-T claim pays for a quarter of FTE coder time.
4. JZ modifier enforcement. Mandatory since July 2023 on single-use vial drug claims with no waste. Practices still receiving denials in 2026 are missing it on at least one claim per provider per week.
5. G2211 commercial payer carveouts. The Medicare add-on code for complex visit management is paid by traditional Medicare and many MA plans, but UnitedHealthcare rebundled G2211 into the E/M base for commercial plans on September 1, 2024. Other commercial payers have followed.
6. IRA Maximum Fair Price effectuation. Ted Okon, Executive Director of the Community Oncology Alliance, told Oncology Business Review that MFP creates a separate reimbursement variable parallel to ASP, which the practice has to bill around in addition to the existing buy-and-bill workflow.

If you do nothing else after reading this article, run a six-line audit on your last commercial remit against the 2026 Medicare fee schedule for the codes above. Most underpayment recoveries start with that single comparison.

The 2026 changes sit on top of fundamentals that have not changed. Those fundamentals start with the diagnostic side of the claim.

ICD-10-CM essentials every oncology practice must master

The two ICD-10-CM rules that drive the most oncology denial rework are encounter sequencing and the active-versus-history-of distinction. Get those wrong and the rest of the chart documentation does not matter.

The sequencing rule for treatment encounters is straightforward. When a patient presents solely for chemotherapy, immunotherapy, or radiation, sequence the encounter code first and the malignancy second. The relevant codes are Z51.0 for radiation, Z51.11 for chemotherapy, and Z51.12 for immunotherapy. If the patient presents for treatment of a complication of the malignancy or its therapy, code the complication first and the malignancy second. Anemia in malignancy (D63.0) is the named exception in the ICD-10-CM Official Guidelines, where the malignancy is sequenced first.

The active-versus-history-of distinction has three traps community oncology practices fall into:

• Hormonal therapy is active treatment. A breast cancer patient on Tamoxifen or Letrozole as adjuvant therapy continues to code as active malignancy (C50.-), not personal history of breast cancer (Z85.3). McLaren Health Plan's coding guidelines name the five-year hormonal therapy window explicitly.
• Leukemia, multiple myeloma, and plasma cell neoplasm codes contain remission status in the code itself. A C91.10 (chronic lymphocytic leukemia, in remission) reports differently from a C91.12 (CLL, in relapse). Personal history Z-codes do not apply.
• Surveillance after treatment completion. Once the tumor has been excised, no further treatment is directed to the site, and there is no clinical evidence of disease, the appropriate code is the personal history Z85.- code, not the active malignancy code.

A practice that audits ICD-10 sequencing on a five-chart sample per provider per quarter catches most of the patterns above before they generate a downstream denial. The economic cost of the audit is far less than the cost of reworking the denials.

ICD-10 establishes the why. The CPT side establishes the what was done, and that is where most of the dollars sit.

CPT essentials for medical oncology

The CPT hierarchy for chemotherapy administration is initial, sequential, and concurrent infusion, and most practices that report flat 96401-96549 ranges to their leadership are masking sequencing errors that change the per-encounter reimbursement. The 96413 to 96417 range is where community medical oncology lives.

The chemo administration logic in plain terms:

• 96413 reports the initial chemotherapy infusion of up to one hour for a single drug. Bill it once per encounter.
• +96415 is the add-on for each additional hour of the same drug. Bill in 30-minute increments past the first hour.
• 96417 reports each additional sequential infusion of a different drug, up to one hour, in the same encounter.
• 96416 reports prolonged infusion requiring use of a portable or implantable pump.
• 96409, 96411 report IV push administration of a chemotherapy agent.

Modifier discipline matters at this layer. Modifier EJ marks the second and subsequent doses of the same drug administered in a course of therapy, which several MA plans require for proper reimbursement. Modifier 25 attached to a same-day E/M flags it as significant and separately identifiable from the procedural service, which payers scrutinize closely in oncology because of the chair-time E/M overlap.

Time documentation is the audit hook. Start and stop times by drug, route of administration, and units administered are required to defend the codes above. The chart that captures only "infusion completed" generates an MAC audit risk on every line.

The ripple effect of getting medical oncology CPT right shows up downstream in operating cost. George Kovach, MD, of Iowa Cancer Specialists, told OncLive that this complexity is what drove community oncology headcount expansion over the past decade.

"In the past, you sent a bill, you put a diagnosis on it, you put a fee on it, and out it went. Now there's more complicated billing, the new coding system, the multiple insurance companies, the authorizations, so you've got to add people to deal with that."

• George Kovach, MD, Iowa Cancer Specialists, OncLive

That headcount cost compounds across modalities. The next one is radiation oncology, where the 2026 changes hit hardest.

CPT essentials for radiation oncology

A radiation oncology course of therapy is a CPT pipeline of seven stages, and the 2026 bundling that hit treatment delivery has compressed the per-fraction reimbursement at the most billable stage in that pipeline. Understanding the pipeline is what allows a practice to spot which 2026 denial is legitimate and which is a payer fee-schedule error.

The CPT pipeline for an external-beam course:

1. Treatment planning. 77261 (simple), 77262 (intermediate), 77263 (complex). One per course.
2. Simulation. 77280 (simple), 77285 (intermediate), 77290 (complex), 77293 (respiratory motion management).
3. 3D radiotherapy plan. 77295. Bundles 77280, 77285, 77290 same date.
4. Dosimetry calculation. 77300. Multiple per course based on plan complexity.
5. Isodose plan. 77306 (simple), 77307 (complex), 77321 (special teletherapy).
6. Treatment devices. 77332, 77333, 77334.
7. Treatment delivery and management. 77385, 77386, 77387 (IMRT delivery), 77401-77417 (conventional delivery), 77427 (radiation treatment management, billed per five fractions).

The 2026 bundling collapsed several treatment delivery codes that previously paid separately. Where a commercial payer's fee schedule still reflects the pre-2026 CPT structure, the claim posts at the lower bundled value while the contracted rate sits unchanged in the system. The dollar gap is silent on the remit unless the practice is running a contracted-versus-paid variance report by code.

Two operating notes the existing radiation oncology guides skip:

• PC/TC split. Freestanding centers bill globally, while hospital outpatient departments split into a professional component (modifier 26) and a technical component (modifier TC). Multi-site practices that treat in both settings most often misbill the modifier on simulation and dosimetry codes.
• Frequency benchmarks. The Noridian Local Coverage Determination L34652 publishes "typical course" frequency expectations: 1 to 6 dosimetry calculations, 1 to 3 isodose plans, 1 to 5 treatment device charges per course, with higher counts (8 or more) for prostate and head-and-neck cases. Where a payer denies for "frequency exceeded" on a case that fits these LCD bands, the appeal letter writes itself.

The CPT pipeline above governs the procedural side of radiation. The drug side is governed by an entirely different rule set, and the dollars at stake there are larger.

High-cost drug billing: J-codes, JW/JZ, NCCN, and the ASP+6% context

Oncology drug billing connects three layers most coding guides treat in isolation: the J-code mechanics on the claim, the NCCN compendium that determines what gets covered, and the ASP+6% economics that determine the margin. A practice owner needs all three because the dollar value of a single drug encounter exceeds most full days of E/M.

J-code mechanics:

• HCPCS J9000 to J9999 cover injectable chemotherapy and biologic agents.
• The NDC of the administered drug is required on the claim line for most commercial payers.
• Units are billed by the HCPCS dosage description, not by vial size. A J-code that descriptor reads "10 mg" and a 100 mg dose administered bills as 10 units.

Drug waste billing in 2026:

• Modifier JW reports documented waste of a single-use vial when the dose administered does not match the available vial size. Document the wasted units on the claim and in the medical record.
• Modifier JZ reports zero waste on a single-use vial. Mandatory since July 2023 on every single-use vial claim with no waste. Missing JZ generates an automatic denial on most MAC and commercial systems.

The NCCN Drugs and Biologics Compendium is the de facto authority for off-label oncology drug coverage. CMS recognizes the compendium for Medicare drug coverage, and most commercial payers pull from it for coverage determinations. The practice-side implication is that the prior authorization packet for an off-label use pulls the NCCN evidence directly into the supporting documentation. A workflow that does not do this generates avoidable denials on routine off-label cases.

The ASP+6% formula sets the underlying Medicare reimbursement rate for buy-and-bill drugs. Payment equals the average sales price plus a 6 percent margin, less the current 2 percent sequester, which functionally reduces the practice margin to ASP+4.3%. A practice that ignores the formula and bills the AWP-based price ends up with a posted contractual adjustment on every drug line and no margin to fund the dispensing infrastructure.

For practices in the orbit of 340B-eligible hospitals, the JG modifier on separately payable drugs flags 340B-acquired product. Jay Ambrad, MD, of Ironwood Cancer and Research Centers and a Community Oncology Alliance board member, has spoken publicly about the consolidation pressure 340B drug pricing puts on independent practices that compete with 340B-eligible hospital outpatient departments.

The Inflation Reduction Act adds a parallel reimbursement variable. Maximum Fair Price for the first 10 negotiated drugs takes effect in 2026. Okon's framing in OBR is that MFP creates an operational layer the practice has to code around because the MFP rate is not ASP, the commercial spillover is unsettled, and the workflow has to reconcile both rates against existing contracted commercial rates.

The drug-billing layer is where dollars per claim are largest. The next section quantifies which dollars actually leak.

Where oncology practices actually lose revenue (and the KPIs to watch)

Three revenue leaks dominate in 2026: silent contract underpayment, denials and rework, and prior authorization labor including retroactive denial. Ranking them by dollar impact and tracking each with a named KPI is what separates practices that recover from 2026 from practices that absorb it.

Leak 1: silent contract underpayment. Underpayment now exceeds outright denial as the top revenue leak in oncology, because high-cost drug claims amplify even a 2 to 3 percent rate variance into six-figure annual losses. Everest A/R's February 2026 analysis frames the math directly: with single drug claims routinely exceeding $20,000, a 2 percent rate variance applied across a thousand claims a quarter is a quarter-million dollars of silent loss. The Doyle 2026 CPT bundling story is the same pattern in radiation oncology. KPIs to track: net collection rate by payer, contracted-versus-paid variance by CPT and HCPCS, and the per-payer fee schedule reconciliation date against the most recent CMS update.

Leak 2: denials and rework. Common drivers in oncology include ICD-10 sequencing errors, missing JZ modifier, missing NDC on drug claims, and exceeded MUE on infusion lines. KPIs: first-pass clean claim rate (target above 95 percent), denial rate by reason code, days in A/R over 90, and denial overturn rate on appeal.

The cash flow risk of late denial detection is acute for solo-administered practices. Anne Slam, the practice administrator of Eastern Connecticut Hematology and Oncology, told Flatiron that her practice systematized denial monitoring after watching the consequences of late detection.

"Before we systematized denial monitoring, we'd have patients come four or five times before we'd receive payment, so now we can make an informed decision on treating the patient."

• Anne Slam, Practice Administrator, Eastern Connecticut Hematology and Oncology, Flatiron

Leak 3: prior authorization labor and retroactive denial. The new wrinkle in 2026 is the retroactive denial pattern Doyle described: payers green-lighting a course of therapy and then denying claims after the fact. The labor side has been building for years. Debra Patt, MD, EVP Texas Oncology and COA President, told AJMC the cost is borne by the practice regardless of the clinical merit of the case.

"Even though my reimbursement has declined, I have to employ people in my office just to manage the prior authorization; I have to write separate letters."

• Debra Patt, MD, EVP Texas Oncology, AJMC

KPIs: prior authorization turnaround time, peer-to-peer rate, retroactive denial rate, and authorization-to-claim match rate.

Ask your RCM team to stand up a five-line monthly dashboard with the metrics above. If the team cannot produce it within 30 days, the dashboard problem is the bigger problem.

What to do this week

The throughline of this oncology coding guide is that the codes alone do not protect your reimbursement. The practice that wins in 2026 treats coding as the front end of the revenue cycle, audits the 2026 changes against actual remits, knows the chemo administration hierarchy and the radiation pipeline cold, and tracks the three revenue leaks above with named KPIs.

Three concrete steps for this week:

1. Run the 2026 fee schedule audit. Pull your last 30 days of commercial remits for the codes named in Section 1. Compare contracted rates against paid rates. Flag every line where the paid rate sits below the contracted rate.
2. Sample-audit ICD-10 sequencing. Pull five charts per provider from the last month. Verify Z51 sequencing on treatment encounters, active-versus-history-of selection on hormonal therapy and surveillance cases, and complication coding on hospitalized patients.
3. Stand up the KPI dashboard. Net collection rate by payer, first-pass clean claim rate, denial rate by reason code, prior authorization turnaround, and contracted-versus-paid variance by CPT. Five lines, monthly cadence.

The contract negotiation work that follows from the audit above is where most of the recoverable dollars sit. Coding accuracy gets the claim out the door correctly; payer contract analysis is what gets the rate priced correctly in the first place. PayerPrice exists for the second half of that workflow.